概括
在高血压男性中,大动脉延展性降低与心脏功能恶化和运动血压反应相关. 某些抗高血压药物可以改善大动脉延伸能力,从而降低心血管风险.
科学领域:
- 心血管医学 心血管医学
- 高血压研究 高血压研究
- 血管生理学 血管生理学
背景情况:
- 持续的基本高血压与心脏缩和心室功能的改变有关.
- 大动脉体积延伸性在缓冲压力变化中起着至关重要的作用.
- 动脉硬和高血压中的心脏重塑之间的相互作用需要进一步阐明.
研究的目的:
- 在高血压男性中研究心脏缩,心室功能和大动脉体积延展性之间的关系.
- 评估不同血管扩展剂对大动脉张张能力的影响.
- 了解动脉硬如何影响心脏适应和对抗高血压治疗的反应.
主要方法:
- 心声图被用来评估心脏缩和心室功能.
- 脉冲波速度测量确定了大动脉体积延伸性.
- 血管扩张效应的比较 (卡德拉,入阻塞剂,异二酸盐) 对大动脉张张能力.
主要成果:
- 降低的大动脉张张能力与运动时血压反应较高,心脏缩增加和缩时间间隔改变有关.
- 血管扩张剂对大动脉张张能力有不同的影响:卡德拉拉没有影响,而入阻塞剂和异二酸盐改善了它.
- 大动脉张张能力下降有助于增加基本高血压的后负荷.
结论:
- 大动脉缓冲功能的改变 (延展能力下降) 导致基本高血压后负荷增加.
- 这会影响心脏缩的程度和心脏功能的变化.
- 选择性使用针对大血管延展性的抗高血压药物可能会影响心血管结果.
相关概念视频
Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Pathophysiology of Cardiac Performance
Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Aortic Regurgitation III: Medical Management
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Hypertension II: Pathophysiology
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...


